A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Necitumumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Aug 2017 The trial was completed in Belgium.
    • 21 Nov 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 11 Nov 2016 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top